Original language | English (US) |
---|---|
Pages (from-to) | 1390-1393 |
Number of pages | 4 |
Journal | Bone Marrow Transplantation |
Volume | 58 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2023 |
Externally published | Yes |
ASJC Scopus subject areas
- Hematology
- Transplantation
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Bone Marrow Transplantation, Vol. 58, No. 12, 12.2023, p. 1390-1393.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma
AU - Knight, Tristan E.
AU - Ahn, Kwang Woo
AU - Hebert, Kyle M.
AU - Atshan, Rasha
AU - Wall, Donna A.
AU - Chiengthong, Kanhatai
AU - Lund, Troy C.
AU - Prestidge, Tim
AU - Rangarajan, Hemalatha G.
AU - Dvorak, Christopher C.
AU - Auletta, Jeffery J.
AU - Kent, Michael
AU - Hashem, Hasan
AU - Talano, Julie An
AU - Rotz, Seth J.
AU - Fraint, Ellen
AU - Myers, Kasiani C.
AU - Leung, Wing
AU - Sharma, Akshay
AU - Bhatt, Neel S.
AU - Driscoll, Timothy A.
AU - Yu, Lolie C.
AU - Schultz, Kirk R.
AU - Qayed, Muna
AU - Broglie, Larisa
AU - Eapen, Mary
AU - Yanik, Gregory A.
N1 - Funding Information: No funding was secured specifically for this project. Dr. Knight reports partial salary support from Hold’Em for Life Oncology Fellowship, Garron Family Cancer Center Research Fellowship, and BMO Financial Group Oncology Fellowship. Dr. Wall reports steering committee participation for CRISPR/Vertex Pharmaceuticals and Editas Medicine; acting as a study advisor for CRISPR/Vertex Pharmaceuticals and Editas Medicine; acting as a clinical trial site-PI for CRISPR Therapeutics, Vertex Pharmaceuticals, and Novartis; and research funding from CRISPR Therapeutics, Vertex Pharmaceuticals, and Novartis. Dr. Rangarajan reports serving as the BMT Medical Monitor for NMDP (no financial reimbursements); and having served as honorary consultant for Medexus. Dr. Dvorak reports consulting for Jazz Pharma, and Alexion Inc. Dr. Auletta reports employment with National Marrow Donor Program (NMDP); and advisory council participation for Ascella Health. Dr. Talano reports research funding from Miltenyi. Dr. Rotz reports acting as a resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT) (employment). Dr. Myers reports research funding for an investigator initiated clinical trial from Incyte and sponsored research from Elixirgen Therapeutics. Dr. Sharma reports consulting for Spotlight Therapeutics, Medexus Inc., Vertex Pharmaceuticals, and Sangamo Therapeutics; research funding from CRISPR Therapeutics. Clinical Trial site-PI: CRISPR Therapeutics, Vertex Pharmaceuticals, Novartis Pharmaceuticals, Magenta Therapeutics, Beam Therapeutics, Honoraria: Vindico Medical Education. Dr. Qayed reports honoraria from Vertex and Novartis.
PY - 2023/12
Y1 - 2023/12
UR - http://www.scopus.com/inward/record.url?scp=85169665242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85169665242&partnerID=8YFLogxK
U2 - 10.1038/s41409-023-02092-3
DO - 10.1038/s41409-023-02092-3
M3 - Letter
C2 - 37666957
AN - SCOPUS:85169665242
SN - 0268-3369
VL - 58
SP - 1390
EP - 1393
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 12
ER -